First clinical experience with belzutifan in von Hippel–Lindau disease associated CNS hemangioblastoma

We present two cases of von Hippel–Lindau (VHL) disease-associated hemangioblastomas in the CNS treated with the newly approved HIF-2α inhibitor, belzutifan. The first case is a 31-year-old female with confirmed pathogenic germline VHL mutation who presented with multiple hemangioblastomas. The pati...

Full description

Bibliographic Details

Published in:	CNS Oncology
Main Authors:	Andrew Dhawan, David M Peereboom, Glen HJ Stevens
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2022-09-01
Subjects:	belzutifan hemangioblastoma VHL von Hippel–Lindau
Online Access:	https://www.futuremedicine.com/doi/10.2217/cns-2022-0008